Price · as of 2025
$31.33
Market cap 1.48B
Valuation
| Metric | Value | Upside |
|---|---|---|
| IC Value | $14.70 | -53% |
| P/E | -28.75 | |
| P/B | 0.93 | |
| P/S | 2.70 | |
| EV/EBITDA | 25.40 | |
| PEG | — | |
| P/TBV | 1.74 |
Valuation history
Annual price overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | IC | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $8.30 | $37.56 | |||
| 2012 | $6.28 | $26.39 | |||
| 2013 | $8.78 | $18.73 | |||
| 2014 | $10.50 | $33.79 | |||
| 2015 | $10.31 | $18.01 | |||
| 2016 | $15.86 | $21.88 | |||
| 2017 | $23.52 | $23.19 | |||
| 2018 | $25.66 | $24.01 | |||
| 2019 | $40.52 | $35.75 | |||
| 2020 | $71.17 | $27.71 | |||
| 2021 | $102.51 | $40.58 | |||
| 2022 | $59.38 | $109.04 | |||
| 2023 | $57.60 | $35.80 | |||
| 2024 | $45.59 | $33.12 | |||
| 2025 | $35.05 | $34.36 |
Historic valuation ratios
Pick a category, then toggle metrics to compare.
Line items
Line items
Line items
About Azenta, Inc.
Azenta, Inc. is a global leader specializing in advanced solutions for the discovery, handling, and preservation of life science samples. The company's operations span across North America, Europe, Asia Pacific (including China), and other international markets. Its business is structured into two main reportable segments: Life Sciences Products and Life Sciences Services. The Life Sciences Products division supplies sophisticated automated systems for the cold storage of chemical compounds and biological specimens. This segment also provides crucial equipment for sample preparation and manipulation, along with various consumables and specialized instruments that empower customers to effectively manage samples throughout their entire research and development workflows. Conversely, the Life Sciences Services segment offers a comprehensive suite of programs for sample management, integrated cold chain logistics, cutting-edge informatics, and a range of sample-centric laboratory services. These offerings are vital for propelling scientific research and accelerating drug development. Key services include secure sample banking, advanced genomic sequencing, gene synthesis, laboratory processing, detailed laboratory analysis, biospecimen acquisition, and other essential support functions. Azenta caters to a diverse client base within the life sciences sector, encompassing pharmaceutical companies, biotechnology firms, biorepositories, and academic or private research institutions. Established in 1978, the company, originally known as Brooks Automation, Inc., officially became Azenta, Inc. in December 2021. Its corporate headquarters are located in Chelmsford, Massachusetts.
- CEO
- John Marotta
- Employees
- 3K
- Beta
- 1.37
Scroll horizontally for additional metrics. Ticker column stays fixed.
| Basic Info | IC Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | Value | Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| AZTA | Azenta, Inc. | $31.33 | 1.48B | $34.36 | +10% | -28.75 | 0.93 | 2.70 | 25.40 | — | 1.74 | 45.52% | -1.90% | -9.39% | -3.19% | -0.31% | -2.68% | 0.06 | — | 2.98 | 2.23 | -3.12 | -60.52% | 3.55% | 210.29% | 2.39% | 0.30 | 2.67% | 0.00% | 0.00% | 0.00% | -121.90 | 35.84 | 2.31 | 4.42 |
| BLFS | BioLife Solutions, Inc. | $33.80 | 1.65B | $18.10 | -46% | -190.81 | 2.36 | 9.11 | 223.44 | — | 5.51 | 64.56% | -1.12% | -12.61% | -1.27% | -0.38% | -1.14% | 0.05 | -0.40 | 5.94 | 4.22 | -4.20 | -43.18% | 16.97% | -92.01% | 0.05% | 0.88 | 0.14% | 0.00% | 0.00% | 0.00% | -745.36 | 1936.85 | 8.37 | 14.87 |
| ESTA | Establishment Labs Holdin… | $91.25 | 2.69B | $25.22 | -72% | -36.75 | 79.69 | 8.89 | -92.65 | — | 151.38 | 69.32% | -18.48% | -24.19% | -133.25% | -17.14% | -14.51% | 11.23 | -1.54 | 3.04 | 1.86 | -8.47 | -42.67% | 27.14% | -22.23% | -3.07% | -0.62 | -28.77% | 0.00% | 0.00% | 0.00% | -52.95 | -35.85 | 9.79 | 2.23 |
| EVO | Evotec SE | $1.98 | 703.38M | $14.39 | +627% | -7.14 | 0.87 | 0.94 | -49.02 | — | 1.39 | 8.27% | -17.87% | -13.13% | -11.26% | -12.23% | -5.39% | 0.55 | -9.75 | 2.07 | 1.87 | -2.10 | -50.00% | -4.98% | -30.94% | -11.10% | -0.02 | -8.83% | 0.00% | 0.00% | 15.22% | -5.03 | -8.65 | 0.90 | 0.27 |
| KMTS | Kestra Medical Technologi… | $25.06 | 1.47B | $17.55 | -30% | -11.53 | 5.85 | 15.95 | -9.12 | — | 5.85 | 51.37% | -141.64% | -138.35% | -56.60% | -220.64% | -40.24% | 0.18 | -17.85 | 4.41 | 4.19 | 0.35 | -52.63% | 59.04% | 15.21% | -7.68% | -1.62 | -190.92% | 0.00% | 0.00% | 0.18% | -10.15 | -11.73 | 14.38 | 6.27 |
| NEOG | Neogen Corporation | $11.40 | 2.49B | $14.31 | +26% | -311.11 | 1.17 | 2.82 | 13.33 | — | -9.03 | 46.93% | -2.48% | -0.91% | -0.38% | -0.80% | -0.23% | 0.00 | -0.38 | 3.82 | 2.10 | -1.09 | -99.20% | -2.71% | -168.82% | 1.30% | 0.53 | 1.34% | 0.00% | 0.00% | 39.43% | -105.20 | 71.23 | 2.61 | 1.35 |
| NVCR | Novocure Ltd | $16.05 | 1.87B | $18.50 | +15% | -9.87 | 3.95 | 2.05 | -9.89 | — | 3.95 | 74.54% | -23.47% | -20.79% | -38.89% | -119.85% | -13.32% | 0.85 | — | 2.90 | 2.57 | -1.57 | -21.79% | 8.28% | 9.32% | -5.63% | -0.22 | -58.98% | 0.00% | 0.00% | 24.77% | -7.65 | -15.55 | 1.80 | 0.31 |
| SDGR | Schrödinger, Inc. | $16.40 | 1.23B | $27.33 | +67% | -8.90 | 2.52 | 3.59 | -6.57 | — | 2.56 | 55.74% | -65.23% | -40.36% | -26.29% | -125.97% | -13.33% | 0.30 | — | 2.75 | 2.64 | 1.26 | -45.14% | 23.29% | -107.56% | 1.36% | 0.07 | 9.40% | 0.00% | 0.00% | 9.99% | -3.79 | 50.78 | 2.47 | 0.45 |
| STAA | STAAR Surgical Company | $22.86 | 1.14B | $7.82 | -66% | -11.61 | 2.71 | 3.90 | -10.67 | — | 3.00 | 76.19% | -19.19% | -33.60% | — | — | — | 0.11 | — | 4.55 | 3.53 | 1.56 | — | — | — | -4.29% | -0.50 | — | 0.00% | 0.00% | 0.69% | -17.08 | -19.59 | 3.28 | 5.14 |
| SYRE | Spyre Therapeutics, Inc. | $104.35 | 9.06B | — | — | -16.46 | 3.57 | — | -8.58 | — | 3.57 | 0.00% | 0.00% | 0.00% | -25.17% | 331.08% | -22.39% | 0.00 | — | 13.25 | 12.89 | 0.41 | -37.74% | — | 7.52% | -6.62% | -2.88 | 267.42% | 0.00% | 0.00% | 0.00% | -8.58 | -10.63 | — | 22.70 |
| TDOC | Teladoc Health, Inc. | $6.93 | 1.26B | $21.18 | +206% | -4.72 | 0.68 | 0.37 | 8.18 | — | -4.86 | 69.50% | -10.39% | -7.92% | -13.93% | -13.07% | -6.05% | 0.75 | -13.34 | 2.69 | 2.43 | 1.76 | -80.58% | -1.54% | 0.91% | 30.17% | 0.73 | 16.68% | 0.00% | 0.00% | 2.87% | -4.58 | 4.22 | 0.48 | -6.29 |
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($14.70 ÷ $31.33) − 1 = -53.08% (IC, example).